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Abstract 
Dermatopontin (DPT) is a small, non-collagenous, and extracellular matrix-associated 
protein that has not been well characterized.  We have previously demonstrated that DPT 
is secreted by adipocytes in the bone marrow.  We have also shown that it can negatively 
regulate hematopoietic stem cell (HSC) homing and engraftment in mice, but the 
mechanism by which it does so remains to be elucidated.  In this study, we found that 
DPT reduced adhesion of whole bone marrow (WBM) and endothelial cells in a dose-
dependent manner.  Interestingly, when WBM cells were incubated with DPT it reduced 
their ability to adhere on top of endothelial cell monolayers.  And using a novel release 
assay, we also demonstrated that DPT could release WBM cells that were already 
adhered to the endothelial cells.  Based on these studies, we hypothesize that DPT is 
delaying HSC homing and engraftment by interacting with or disrupting integrin 
receptors that are critical for transmigration across the endothelial barrier. 
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Introduction 
 
Hematopoietic Cell Transplantation 
 
 Over the past 50 years, hematopoietic cell transplantation (HCT) has become a 
well-established treatment option for patients suffering from a variety of hematopoietic 
disorders.  HCT was pioneered in the mid-20th century by Edward Donnall Thomas.  He 
reported the first use of intravenous infusions of bone marrow, following radiation and 
chemotherapy, to treat patients with cancer1–3.  Thomas based his early clinical work on 
evidence that showed mice could survive lethal doses of whole body irradiation if the 
spleen or bone marrow were shielded4.  Later evidence indicated that transplanted spleen 
homogenate or bone marrow could confer protection to irradiation5–10.  These findings 
led Thomas to attempt the first human bone marrow transplant (BMT) between identical 
twins3,11.   
Following the success of Thomas—and a furthered understanding of human 
leukocyte antigen (HLA)-matching—Robert A. Good successfully performed the first 
BMT between non-siblings at the University of Minnesota in 196812.  This likely 
solidified the future usefulness of HCT.  Today, over 50,000 HCTs are performed 
annually to treat diseases including acquired hematological malignancies and inherited 
disorders13–15.  The work of Thomas and Good paved the way for HCT to become a well-
established and life-saving standard of care for patients suffering from diseases and 
disorders including cancers of the blood and immune system, anemia, immune system 
deficiencies, and inborn errors of metabolism11,16,17. 
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Hematopoietic Stem Cells and the Hematopoietic Niche 
 HCT is an effective treatment option for hematological diseases and disorders due 
to unique properties possessed by hematopoietic stem cells (HSCs).  HSCs have been 
studied in depth over the last 50 years and were one of the first stem cells to be 
characterized9,10.  Because billions of blood cells must be replenished every day, 
hematopoiesis is a carefully regulated through an orchestrated process of differentiation 
and self-renewal.  In healthy individuals, the relatively rare population of multipotent 
HSCs can effectively maintain the entire hematopoietic system.  To form all of the major 
blood cell lineages—erythroid, myeloid, and lymphoid—a limited pool of HSCs18,19 
differentiate into committed progenitor cells, which subsequently terminally differentiate 
to form every type of blood cell in the body20.  The HSCs also undergo a tightly regulated 
self-renewal process in order to maintain the small pool of HSCs21.  Taking advantage of 
the self-renewal and differentiation characteristics, HCT is utilized to replace and rebuild 
a patient’s damaged or defective hematopoietic system using HSCs from a healthy donor.  
The hematopoietic niche is integral in maintaining and regulating the quiescence, 
self-renewal, and differentiation of HSCs22–27.  The niche is a specialized 
microenvironment located within the bone marrow.  It consists of a vascular niche, which 
regulates differentiation and proliferation as well as an osteoblastic niche which regulates 
quiescence and self-renewal23,27–30.  The niche consists of a diverse population of bone 
marrow cell types including osteoblasts, endothelial cells, and stromal cells27,29.  These 
cells provide physical contact and chemical signaling necessary for maintaining and 
regulating the self-renewal and differentiation characteristics of HSCs22,23,25,26,31,32.  
  3 
Importantly, bone marrow cells in the hematopoietic niche also produce chemokines that 
have been implicated in migration, retention, and homing of HSCs33–36. 
 
Hematopoietic Stem Cell Homing 
HSCs can enter the blood stream via endogenous mobilization37, induced 
mobilization by drugs38, or intravenous delivery during HCT39.  Once in the peripheral 
circulation, HSCs undergo active navigation back into the bone marrow, a process that is 
known as “homing.”  HSCs naturally home to specific tissues during development; early 
in development starting in the aorta gonad mesonephros (AGM) region and homing to the 
fetal liver and then from the fetal liver to the bone marrow as development progresses.  
HSC migration and homing in the adult organism play an important role in bone marrow 
homeostasis33.  Stress signals or radiation- or chemotherapy-induced tissue damage can 
also cause HSCs to mobilize and re-home to the bone marrow40,41.  HCT takes advantage 
of the homing capability of HSCs because transplanted cells will home to the bone 
marrow in response to a chemoattractant gradient and tissue damage (caused by total 
body irradiation, or TBI, and/or chemotherapy), much like the homeostatic process33,42,43. 
The homing mechanism utilized by HSCs is a complex, multi-step process that is 
not really understood.  To attract circulating HSCs to the bone marrow, cells in the 
hematopoietic niche secrete chemokines and other factors.  This establishes a 
chemoattractive gradient in which the hematopoietic niche has relatively high 
concentration of signaling molecules while the peripheral blood does not.  Stromal 
derived factor-1 (SDF-1; CXCL12) and its receptor, CXCR4, have been implicated as the 
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main chemoattractive axis in HSC migration, retention, and homing36,44.  Secretion of 
SDF-1—by stromal cells, mesenchymal stem cells, perivascular cells, and osteoblasts 
that are located in the bone marrow33,34,36,45—can be induced by bone marrow tissue 
damage or other stress signals41,46,47.  The CXCR4 receptor is constitutively expressed on 
HSCs and can be upregulated in response to stem cell factor (SCF) and hypoxia inducible 
factor-1 (HIF-1), which are also secreted by cells in the hematopoietic niche33.  This 
dynamic expression of SDF-1/CXCR4 allows the hematopoietic niche to signal the 
mobilized HSCs and initiate the homing process, which occurs relatively rapidly. 
In addition to acting as a chemoattractant, SDF-1 also stimulates the upregulation 
of adhesion molecules required for HSC transendothelial migration through the bone 
marrow endothelial barrier43.  Similar to leukocyte extravasation, once mobilized HSCs 
enter the microvasculature of the bone marrow they are prompted to undergo rolling 
adhesion that is mediated by P- and E-selectin molecules on the bone marrow endothelial 
cells (BMECs)48,49 (Figure 1A).  Further cytokine and juxtacrine signaling initiates the 
tight adhesion of HSCs to the BMECs.  This tight adhesion relies on the binding of the 
integrin receptor very late antigen-4 (VLA-4) to vascular cell adhesion protein 1 
(VCAM-1) and intercellular adhesion molecules 1 (ICAM-1) engagement with 
lymphocyte function-associated antigen 1 (LFA-1)35 (Figure 1B).  Both VLA-4 and 
LFA-1 are upregulated by SDF-1 stimulation prior to the HSC-BMEC adhesion33.  The 
tightly adhered HSCs then extravasate and enter the bone marrow (Figure 1C).  This 
extravasation (also known as diapedesis) is also mediated by VLA-4 and -5, which are 
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thought to pull the HSCs along the extracellular matrix (ECM) protein fibronectin to 
enter the bone marrow proper35,50. 
Following successful transendothelial migration, HSCs then go through a process 
known as lodgment.  Lodgment occurs briefly as HSCs are traversing the marrow, 
migrating to bone marrow regions specific to the hematopoietic niche (Figure 1D).  
Transmembrane-bound SCF (tm-SCF)51, hyaluronic acid (HA)52, and osteopontin 
(OPN)53 have all been implicated in lodgment.  However, due to the lack of a suitable in 
situ models, difficulties in labeling and tracking individual or small populations of cells 
in the bone marrow and a large functional overlap between adhesion molecules and 
receptors, a detailed understanding of the lodgment process is not readily obtainable54. 
 In the context of HCT, transplanted HSCs that have successfully traversed the 
bone marrow during lodgment then undergo engraftment in the hematopoietic niche 
(Figure 1D).  Successful engraftment also depends upon cell-cell contact and cytokine 
signaling54, much like homing and lodgment.  Unlike homing and lodgment, however, 
successful engraftment requires cell division; once in the hematopoietic niche, 
transplanted HSCs will begin proliferating and differentiating33.  Donor-derived short-
term HSCs (ST-HSCs) and other hematopoietic progenitors serve as the primary source 
of blood cells early after transplantation (weeks to months).  Stable re-establishment of 
the hematopoietic system occurs with the engraftment of donor-derived long-term HSCs 
(LT-HSCs)33,55.  A significant delay or inhibition of the homing process impedes 
successful engraftment of LT-HSCs and will ultimately lead to graft failure. 
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Figure 1: Summary of adhesive interactions between HSCs and BMECs during 
homing. 
 
 
Figure 1:  This figure was adapted from Peled et al.35  Stromal cells in the bone marrow secrete 
SDF-1, creating a chemoattractive gradient that recruits circulating HSCs to the bone marrow.  
HSCs bear the SDF-1-specific receptor, CXCR4.  (A) Rolling adhesion is initiated by P- and E-
selectins on the surface of BMECs.  (B) Tight adhesion occurs when VLA-4-bearing HSCs bind 
to VCAM-1 on BMECs.  ICAM-1 also engages LFA-1 during tight adhesion.  (C) 
Transendothelial migration (diapedesis) follows tight adhesion and is mediated by VLA-4 and -5 
which pull the HSCs along the ECM protein fibronectin.  (D) HSCs then traverse the bone 
marrow to regions of the hematopoietic niche, where they will interact closely with various 
support cells.  Migration through the bone marrow is known as lodgment and engraftment occurs 
when HSCs enter the niche and begin proliferation and differentiation.  BMECs: bone marrow 
endothelial cells; HSCs: hematopoietic stem cells; ICAM-1: intracellular adhesion molecule-1; 
LFA-1: lymphocyte function-associated antigen 1; SDF-1: stromal derived factor-1; VCAM-1: 
vascular cell adhesion molecule-1; VLA: very late antigen. 
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Homing-Associated Graft Failure 
 Despite the success of HCT over the past 50 years, the procedure is still 
associated with significant morbidity and mortality11.  GVHD, disease relapse, infection, 
and graft failure all represent major obstacles for HCT success.  Of these, graft failure is 
one of the most fatal HCT complications and has an incidence rate of up to 5% in the 
case of allogeneic-HCT56–60.  It may be difficult to pinpoint the exact cause of graft 
failure as a number of factors can ultimately cause graft failure during HCT.  First, if an 
inadequate number of donor-derived HSCs are transplanted into a patient, there may not 
be enough HSCs present to establish a functioning hematopoietic system; such is 
commonly the case for umbilical cord-derived HSCs57.  Second, immunologic destruction 
(host versus graft) likely accounts for a vast majority of graft failures61 and is mediated 
by persistent endogenous immune cells56.  The immune-mediated destruction of 
transplanted HSCs occurs as early as homing and lodgment processes, preventing 
engraftment from even occurring.  A third point of failure is GVHD, in which immune 
cells within the transplanted tissue react against the host’s body.  And finally, it is 
hypothesized that irradiation- or chemotherapy-induced tissue damage in the bone 
marrow may induce certain resident bone marrow cells, such as adipocytes, to secrete 
factors that may delay or impede successful HSC homing or proliferation53,62,63. 
 
Role of Adipocytes in the Hematopoietic Niche 
 Adipocytes, like endothelial cells and other stromal cells, are present in and 
around the hematopoietic niche in the bone marrow64.  While a vast array of research has 
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gone into understanding how hematopoietic niche cells regulate and influence 
hematopoiesis and HSC homing and engraftment65, the definitive role of adipocytes in 
these processes remains unclear.  A thorough study by Naveiras et al. found that bone 
marrow taken from adipocyte-rich bones had an overall reduction in the number of 
hematopoietic progenitor cells and that HCT into genetically fatless (A-ZIP/F1) mice 
lead to an enhanced recovery of the hematopoietic system66.  This indicates that HSCs 
more readily engraft in the absence of adipocyte infiltration into the hematopoietic niche, 
which occurs with age or after irradiation or chemotherapy.  Intriguingly, Naveiras et al. 
also reported that adipocytes could reduce in vitro expansion of hematopoietic cells, 
likely via secreted, diffusible inhibitors66.  This finding was reinforced by additional 
reports showing the adipocyte-secreted factors neuropillin-167, lipocalin 268, 
adiponectin63, and tumor necrosis factor (TNF)-α69 are each capable of suppressing 
hematopoietic proliferation.  However, the exact adipocyte-derived mediators causing 
reduction in homing or engraftment efficiency have not been identified. 
 Preliminary data gathered by our lab (all unpublished data) supports the 
hypothesis that adipocyte-rich regions of the bone marrow recruit and engraft 
hematopoietic cells less efficiently when compared to adipocyte-poor regions.  In support 
of Naveiras et al., we found that donor-derived murine HSCs prefer to home to the 
proximal half of the tibia, which is an adipose-poor region of bone marrow in mice.  To 
identify possible adipocyte-secreted signaling factors (adipokines) that may account for 
the disparity between HSC homing to adipocyte-rich bone marrow versus adipocyte-poor 
bone marrow, we performed gene expression analysis on populations of murine 
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adipocytes and CD45+ hematopoietic cells.  Nineteen genes encoding for chemokines, 
cytokines, or extracellular factors were expressed at least 2-fold higher in adipocytes 
versus the CD45+ hematopoietic cells.  Of these genes, we chose to focus on the small, 
secreted protein dermatopontin (DPT).  DPT had high expression in adipocytes and was 
shown to be localized to adipocyte-rich areas in the bone marrow.  Like other 
chemokines that affect hematopoietic cell behavior, DPT was highly induced in the bone 
marrow after irradiation and plasma levels of DPT were elevated for 1-2 days post-
radiation.  Unlike the other adipokines discussed previously, DPT does not appear to 
inhibit cell proliferation or differentiation, as shown using colony forming unit (CFU) 
assays.  However, it was revealed that DPT can significantly impair homing and 
engraftment if mice were pre-treated with a bolus of 2 µg of DPT 30 to 60 minutes prior 
to HCT.  CFU assays done on peripheral blood following transplant revealed a higher 
number of CFUs were present in the blood compared to untreated mice, indicating that 
transplanted HSCs were “stuck” in circulation.  Together, these preliminary findings (all 
unpublished data) indicate that DPT is secreted by adipocytes, both naturally and in 
response to radiation-induced injury, and that the secreted DPT negatively modulates 
HSC homing and engraftment.  The exact mechanism by which DPT regulates these 
processes is unknown. 
 
Dermatopontin 
DPT, also known as tyrosine-rich acidic matrix protein (TRAMP), is a 22 kDa 
ECM-associated protein that was first discovered in bovine fetal skin70.  DPT is 
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composed of 183 amino acids, of which 20 are tyrosine residues.  The protein structure 
consists of five loops, four of which interestingly contain the same repeating residue 
sequence D-R-E/Q-W-X-F/Y.  However, the significance of the loop structure or residue 
sequence has not been demonstrated.  Another residue sequence of note is N-Y-D71, 
which may have lysyl oxidase activity that can cross-link collagen72 among other 
proteins, allowing DPT to modify the ECM. And finally, DPT contains a candidate 
integrin-binding residue sequence, R-G-A-T71,73, indicating the DPT molecule likely 
interacts with integrin receptors, as has been shown by several studies74–80.  
Unlike other non-collagenous ECM proteins, DPT has not been extensively 
characterized.  In addition to bovine, DPT expression was found to be conserved amongst 
other mammals81, including humans82.  Expression has also been documented in 
zebrafish83, birds81, and invertebrates such as crabs and mollusks84.  This indicates DPT 
may have a critical function in the body.  In addition to the skin, DPT is widely 
distributed throughout the kidney, liver, heart, eye, muscle, bone matrix and brain71,83,85–
88.  Whether or not DPT has a physiological role in the hematopoietic system or bone 
marrow remains to be observed. 
 Previous studies have shown that DPT interacts with a number of other ECM 
proteins and can modify their biological activity, hinting at a possible physiological role 
for DPT.  Because DPT was discovered by co-purification along with decorin70, there is a 
clear relationship between the decorin and DPT molecules, which later evidence 
supported71,89.  In vitro studies have revealed that DPT interacts with fibrin, fibrinogen, 
and fibronectin, promoting fibrillogenesis and enhancing their biological activity77–79.  
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Additionally, a comprehensive study revealed that targeted disruption of DPT using 
dermatopontin-null mice caused abnormal collagen fibrillogenesis, a decrease in the 
collagen content of skin, an increase in skin elasticity, and a thinner dermis90.  A separate 
study using the same dermatopontin-null mouse found defects in collagen fibrils and a 
decrease in the thickness of the corneal stroma86,91.  Overall, dermatopontin-null mice 
were mostly normal although the hematopoietic system was not examined.  And 
furthermore, a small number of studies have revealed that DPT can enhance or inhibit the 
biological activity of signaling pathways or secreted signaling factors88,89,92.  Taken 
together, these studies reveal that DPT can regulate the biological activity of numerous 
other ECM components and may have an influence on cellular signaling networks. 
 Since the ECM is a critical component involved in cell adhesion, DPT likely plays 
a major role in regulating the adhesive properties of cells in the body.  DPT also appears 
to be involved in the response to injury because it is upregulated after irradiation.  
Supporting this fact, DPT was observed to promote migration and adhesion of epidermal 
keratinocytes (HaCaT cells)74 as well as cardiac fibroblasts75 in vitro.  DPT expression 
has also been found in the infarct zone following heart attack in rats93 and the wound 
fluid in skin after injury78.  Additional reports demonstrated that DPT increases adhesion 
of epithelial (HT1080)78 and cancer cells80 in vitro.  Because it can alter cell adhesion in 
vitro, DPT has been hypothesized to modulate adhesive properties of cells in vivo, 
playing an important role in the wound healing process71.  This is of interest since 
radiation and chemotherapy preparative regimens that precede HCT cause significant 
damage to body tissue, particularly the bone marrow vasculature and stroma.   
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As previously mentioned, preliminary data obtained by our lab has shown that 
adipocytes in the bone marrow secrete DPT, especially in response to fatal injury caused 
by lethal irradiation.  Mice pre-treated with DPT prior to HCT showed significantly 
reduced homing and engraftment of transplanted WBM.  These data indicated that DPT is 
a negative regulator of homing and engraftment, which has never been demonstrated of 
an adipokine.  If DPT is playing a crucial role in bone marrow wound healing—by 
altering the adhesive properties of cells—it may be inadvertently preventing efficient 
homing and engraftment of HSCs.  However, due to the lack of studies involving DPT in 
the context of the hematopoietic system, the exact mechanism by which DPT affects the 
homing and engraftment processes remains uncertain.  We hypothesized that 
dermatopontin can alter adhesive properties of the extracellular matrix or block 
integrin receptors on endothelial and bone marrow cells, thereby negatively 
regulating the homing and engraftment processes. 
To address this hypothesis, we performed adhesion assays to determine how DPT 
affected WBM and endothelial cell adhesion to plastic and other ECM proteins in vitro.  
Because DPT may reduce WBM cell adhesion to vasculature, we also performed in vitro 
adhesion assays and measured the effect of DPT on WBM cell adhesion to endothelial 
monolayers.  In vitro transwell migration assays were utilized to determine if DPT 
affected WBM cell homing through endothelial monolayers as well.  And finally, 
candidate integrin receptors thought to bind DPT were assessed using flow cytometry.  
WBM cells were used in these experiments rather than a more defined population of 
hematopoietic cells because WBM better represents what patients would receive when 
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undergoing BMT.  There is also evidence that donor-derived stromal cells from the 
hematopoietic niche are important for successful engraftment after BMT94,95.  It is 
possible that DPT negatively regulates the homing and engraftment processes by 
interacting with these beneficial stromal cells.  Therefore, we utilized WBM in our 
experiments as it contains both HSCs and stromal support cells important for HCT. 
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Materials and Methods 
Antibodies and Reagents 
Anti-integrin α3 antibodies (#sc-6587) and anti-integrin β1 antibodies (sc-6622) 
were purchased from Santa Cruz Biotechnology (Dallas, Texas).  Anti-integrin α5 
antibodies were purchased from BioLegend (#103807; San Diego, CA). 
Human fibronectin was purchased Sigma-Aldrich (#F2006; St. Louis, MO).  
Human osteonectin was purchased from EMC Millipore (#499250; Villerica, MA).  
Human osteopontin (#1433-OP-050/CF), human vitronectin (#2349-VN-100), pre-coated 
vitronectin plates (#CWP003), recombinant mouse decorin (#1060-DE-100), 
recombinant mouse dermatopontin (rDPT; #5749-DP), and recombinant mouse sdf-1α 
(#460-SD-010) were all purchased from R & D Systems (Minneapolis, MN).  Retronectin 
was purchased from Takara (#T100A; Mountain View, CA).  TNF-α was purchased from 
Peprotech (#300-01A; Rocky Hill, NJ).  
 
Cell Culture 
 Endothelial cell lines were cultured and used for a variety of in vitro adhesion 
assays and release assays.  We chose to test the effect of DPT on endothelial cell 
adhesion since the bone marrow vasculature represents a major obstacle to homing HSCs.  
Endothelial cells were also used to create monolayers in transwell migration baskets to 
create an endothelial barrier for migrating WBM cells.  And flow cytometry was utilized 
to determine if integrin antibodies could inhibit DPT from binding endothelial cells as we 
hypothesized that DPT may be coating the vasculature in the bone marrow. 
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The human umbilical vein endothelial cell (HUVEC) line was purchased from 
Lonza (#C2519A; Basel, Switzerland) and cultured as a monolayer at 37°C.  HUVECs 
were maintained in Endothelial Growth Medium™-2 BulletKit™ (EGM-2) media (#CC-
3162; Lonza) and passaged or used for experimentation when 80-90% confluent.  
HUVEC media was changed every two days.   
The human dermal microvasculature endothelial cell (HDMEC) line was 
purchased from ScienCell (#2000; Carlsbad, CA) and cultured as a monolayer at 37°C.  
As per supplier recommendation, HDMECs were cultured in endothelial cell medium 
(ECM) which was also purchased from ScienCell (#1001).  The ECM media was 
supplemented with 25 mL FBS, 5mL endothelial growth supplement, and 5 mL 
penicillin/streptomycin solution, all of which came with the media kit.  ECM media was 
replaced every two days, as directed, and cells were passaged when 80-90% confluent. 
The VeraVec™ mouse bone marrow endothelial cell (BMEC) line was purchased 
from Angiocrine Bioscience (#mVera-bon-01; New York, NY) and cultured as a 
monolayer at 37°C in an incubator with 5% CO2/5% O2.  BMECs were maintained in a 
complete mouse endothelial cell media which consisted of advanced DMEM/F12 media 
(#12634-010; Life Technologies, Carlsbad, CA), 50 µg/mL endothelial cell supplement 
(#J64516; Alfa Aesar; Heysham, United Kingdom), 20% FBS, 1% antibiotic-antimycotic 
solution (#15240-061; Invitrogen, Carlsbad, CA), 10 mM HEPES buffer (#25-060-Cl; 
Mediatech, Inc.; Herndon, VA), 5 µM SB431542 small molecule (#1614; R & D 
Systems), 50 µg/mL heparin (#25021-400-10; Sagent Pharmaceuticals; Schaumburn, IL), 
1X Glutamax™ solution (#35050-061; Life Technologies), 1% non-essential amino acids 
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(#11140-050; Life Technologies), 20 ng/mL fibroblast growth factor-2 (FGF-2; #100-
18B, Peprotech), and 10 ng/mL vascular endothelial growth factor (VEGF; #450-32; 
Peprotech).  Because FGF-2 and VEGF degrade in solution, they were added directly to 
the culture flask whenever the media was changed.  Media change occurred every two 
days and BMECs were passaged when 100% confluent, as suggested by supplier.   
Human mesenchymal stem cells (huMSCs) were cultured in MSC media which 
contained minimal essential medium (MEM)-alpha, 10% FBS, 1% Glutamax, and 1% 
penicillin/streptomycin (#15070-063; Life Technologies).  MSC media was changed 
every two days and huMSCs were passaged when 80-90% confluent. 
 
Murine Bone Marrow Isolation 
 Whole bone marrow (WBM) was isolated for use in a variety of in vitro adhesion 
assays, release assays, and migration assays.  We chose to use WBM in these assays 
instead of a more defined population of HSCs. This was done because patients 
undergoing BMT receive WBM during the transplant opposed to receiving only 
hematopoietic cells, so we wanted our assays to better represent the population of cells 
that would be transplanted under normal conditions. 
Young mice were euthanized using CO2 and subsequently perfused with 10 mL of 
PBS.  Long bones from the hind legs were dissected out and cleared of muscle and 
connective tissue.  Bone marrow was harvested by crushing the dissected bones in a 
pestle containing 5 mL PBS + 2% fetal bovine serum (FBS; referred to as PBS+).  
Supernatant was filtered through a 40 µm nylon filter and placed on ice.  Remaining bone 
fragments were incubated with 5 mL of Accutase (#07920; StemCell Technologies; 
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Vancouver, Canada) for 10 minutes at 37°C to release remaining bone marrow cells.  
After incubation with Accutase, bone marrow fragments were diluted and washed three 
times using 5 mL cold PBS and filtered through a 40 µm filter into the primary filtrate.  
The cell suspension was then spun down at 600g for 5 minutes at 4°C.  Red blood cells 
were then lysed with 1X RBC Lysis Buffer (#420301; BioLegend), according to 
manufacturer’s recommendations.  WBM cells were then washed twice with PBS+ and 
used directly for experimentation or further enrichment. 
Sca1+ Enrichment 
 Sca1+ cells were enriched from isolated WBM for use in determining how DPT 
dosage affected hematopoietic cell adhesion in vitro.  We enriched for Sca1+ cells 
because they represent a more refined population of hematopoietic cells located within 
WBM.  Sca1+ cell enrichment was performed by magnetic separation using the 
EasySep™ Mouse Sca-1 Positive Selection Kit (#18756; StemCell Technologies) 
according to manufacturer’s recommendations.  Following enrichment, Sca1+ cells were 
suspended in PBS+. 
 
Zebrafish Whole Kidney Marrow Isolation 
 Whole kidney marrow (WKM) as isolated from zebrafish for use in adhesion 
assays.  WKM was used because we wanted to assess whether or not DPT affected 
adhesion of cells from a non-mammal animal. 
Zebrafish were euthanized by rapid cooling in 4°C water.  Kidneys were dissected 
as previously described96.  Briefly, forceps were used to tease the kidney tissue away 
from the body, starting from the anterior end and working towards the posterior.  The 
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dissected kidneys were then placed in PBS+ and thoroughly homogenized by rapid 
pipetting.  Suspension was filtered through a 40 µm filter and the cells were spun down at 
500g for 5 minutes at 4°C.  Whole kidney marrow (WKM) cells were washed three times 
with PBS+. 
 
CellTracker™ Green CMFDA Staining 
 To fluorescently label cells for use in adhesion, release, and migration assays, 
CellTracker™ Green CMFDA dye (CT Green; #C2925; Life Technologies) was utilized 
according to manufacturer’s recommendations.  Briefly, after harvesting cells they were 
re-suspended in 10 mL of PBS+ containing 2.5 µM CellTracker™ Green CMFDA dye.  
Cells were stained for 30-60 minutes at 37°C in an incubator.  After staining, cells were 
allowed to recover in 10 mL of appropriate media for 30-45 minutes at 37°C.  Cells were 
washed twice with PBS+, placed on ice, and used directly in experimentation. 
 A CT Green lysis buffer was formulated as a 10X solution containing 5% 
Triton™ X-100 (#X100; Sigma-Aldrich) dissolved in Hank’s balanced salt solution 
(HBSS) without phenol red (#14025092; Life Technologies).  Lysis buffer was further 
diluted 1:10 in HBSS just prior to use. 
 
ECM Adhesion Assays 
 To determine how well WBM cells adhere to various ECM proteins, wells of a 
black, 96-well tissue culture plate were coated with 20 µg/mL decorin, fibronectin, 
osteonectin, osteopontin, retronectin, or vitronectin overnight at 4°C.  Negative control 
wells were coated with 100 µL PBS.  The next day, wells were blocked at room 
temperature for two hours with a solution of 5% bovine serum albumin (BSA; #A2153; 
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Sigma-Aldrich) in PBS.  During blocking, BSA binds to any plastic that was not bound 
by the previous proteins.  After blocking, wells were washed twice with PBS.  CT Green-
stained WBM cells were suspended in PBS+ and inoculated into each well at a density of 
1.5 x 105 cells/well.  Cells were allowed to adhere for 1 hour at 37°C in an incubator.  
After incubation, wells were carefully washed three times with PBS.  Cells were then 
lysed with 100 µL of 1X CT Green lysis buffer.  Fluorescence intensity was measured 
with a BioTek® Synergy 2 (BioTek; Winooski, VT) plate reader using a 485 nm 
excitation laser. 
 We utilized a similar adhesion assay to determine how DPT affects WBM cell 
adhesion to wells that were instead coated with a cocktail of the ECM proteins.  Wells 
were instead coated with a protein cocktail containing decorin, fibronectin, osteonectin, 
osteopontin, and vitronectin; each at a concentration of 50 µg/mL.  Total coating volume 
was increased to 250 µL instead of 100 µL.  ECM cocktails that received DPT were 
inoculated with a total of 4 µg of DPT just after other ECM molecules were added.  
Wells that did not receive DPT were instead inoculated with an equivalent volume of 
PBS.  DPT was thoroughly mixed in to the cocktail via pipetting. 
 
Cell Adhesion to Plastic 
 We hypothesized that DPT reduced the overall adhesiveness of cells and therefore 
that cell adhesion to plastic would be reduced in the presence of DPT.  To test this, we 
conducted very fundamental adhesion assays, in which WBM cells or endothelial cells 
were incubated with DPT and allowed to adhere to a tissue culture plate. 
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Assays involving cell adhesion to plastic were conducted as follows:  CT Green-
stained cells were suspended in RPMI media 1640 (#32404-014; Life Technologies).  
DPT was added to the RPMI media at a final concentration of 36 µg/mL.  Control 
samples received an equivalent volume of PBS instead.  Cells were allowed to incubate 
with DPT for 3 minutes at room temperature.  The wells of a black, 96-well plate were 
then seeded at a density of 5 x 104 cells/well.  Cells were allowed to adhere for 1 hour at 
37°C in an incubator.  Following incubation, wells were carefully washed once with PBS 
and lysed with 100 µL of 1X CT Green lysis buffer.  Fluorescence intensity was 
measured with a BioTek® Synergy 2 plate reader using a 485 nm excitation laser. 
 In experiments with TNF-α activation of endothelial cells, TNF-α was added to 
culture media at a concentration of 2 ng/mL the day before the experiment. 
 
Aorta Immunohistochemistry 
 To determine if DPT binds to vasculature, we dissected aortas, incubated them 
with DPT and performed immunohistochemistry.  Aortas were carefully dissected from 
mice and rinsed with PBS.  One end of the aorta was sutured shut.  The aorta was then 
filled with a 0.5 µg/µL DPT solution (~5 µL) and clamped shut.  It should be noted that 
this is in excess of physiological concentrations, which are measured in the range of 
pictograms per milliliter after irradiation.  The aortas were then incubated at 37°C for 1 
hour.  Following incubation, the DPT solution was removed and the aortas were washed 
with PBS.  They were then frozen in Tissue-Tek® optimal cutting temperature (O.C.T.) 
compound (#4583; Sakura, Torrance, CA) and sent to the Histology and Microscopy 
Core Facility at the University of Minnesota for processing and immunohistochemistry 
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(IHC).  IHC against DPT was performed using an anti-6X His tag® antibody (#ab9108; 
Abcam, Cambridge, MA). 
Cell Adhesion Assays 
DPT has been associated with numerous ECM proteins and has been shown to 
modulate their biological activity.  We hypothesized that DPT may be affecting cell 
adhesion by interacting with ECM proteins important for the adhesion process.  To test 
this hypothesis, we performed adhesion assays in which WBM, WKM, or endothelial 
cells were allowed to attach to fibronectin- or vitronectin-coated tissue culture plates in 
the presence or absence of DPT. 
 
WBM Adhesion to Vitronectin 
For the experiment involving WBM cell adhesion to vitronectin, pre-coated 
vitronectin plates purchased from R & D Systems were used.  CT Green-stained WBM 
cells were suspended in PBS+ and inoculated into each well at a density of 1.5 x 105 cells 
per well.  Wells that received DPT were inoculated with a total of 2 µg of DPT along 
with the cells.  Wells lacking DPT were inoculated with an equivalent volume of PBS.  
Cells were allowed to adhere at 37°C for 1 hour.  After incubation, wells were carefully 
washed three times with PBS.  Cells were then lysed with 100 µL of 1X CT Green lysis 
buffer.  Fluorescence intensity was measured with a BioTek® Synergy 2 plate reader 
using a 485 nm excitation laser.  
 
WKM Adhesion to Fibronectin 
 Wells of a black, 96-well plate were coated with 20 µg/mL fibronectin overnight 
at 4°C.  The next day, wells were blocked with a solution of 1% BSA in PBS for 1 hour 
  22 
at room temperature.  Wells were then washed once with PBS.  CT Green-stained WKM 
cells were suspended in PBS+.  DPT was added to cells at a final concentration of 20 
µg/mL.  Control samples received an equivalent volume of PBS instead.  A black, 96-
well plate was then seeded with the cells at a density of 3 x 104 cells/well.  Cells were 
allowed to adhere for 2 hours at 37°C in an incubator.  Following incubation, wells were 
washed twice with PBS and lysed with 100 µL of 1X CT Green lysis buffer.  
Fluorescence intensity was measured with a BioTek® Synergy 2 plate reader using a 485 
nm excitation laser. 
 
HUVEC Adhesion to Vitronectin 
 A pre-coated vitronectin plate was used.  CT Green-stained HUVECs were 
suspended in PBS+ and inoculated into each well at a density of 3 x 104 cells/well.  Wells 
that received DPT were inoculated with a total of 1 µg of DPT along with the cells.  Cells 
were allowed to adhere at 37°C for 2 hours.  After incubation, wells were carefully 
washed twice with PBS.  Cells were then lysed with 100 µL of 1X CT Green lysis buffer.  
Fluorescence intensity was measured with a BioTek® Synergy 2 plate reader using a 485 
nm excitation laser.  
 
HDMEC Adhesion to Fibronectin 
 Wells of a black, 96-well plate were coated with 20 µg/mL fibronectin ± 1 µg 
DPT overnight at 4°C.  CT Green-stained HDMECs were suspended in ECM media and 
inoculated on to the late at a density of 1.5 x 105 cells/well.  Cells were allowed to adhere 
overnight in a 37°C incubator.  The next day, wells were gently washed with PBS and 
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were then lysed with 100 µL of 1X CT Green lysis buffer.  Fluorescence intensity was 
measured with a BioTek® Synergy 2 plate reader using a 485 nm excitation laser. 
 
Dosage Assays 
 We wanted to know if DPT affected cell adhesion in a dose-dependent manner.  
To test this, we assayed the adhesion of various cell types to wells coating with 
increasing concentrations of DPT. 
Wells of a black, 96-well plate were coated with the indicated concentrations of 
DPT overnight at 4°C.  The next day, wells were blocked with a solution of 1% BSA in 
PBS for 1 hour at room temperature.  Wells were then washed with PBS.  Cells were 
inoculated on to the plate at a density of 3 x 104 cells/well.  In the case of the HDMECs, 
the cell density was 1.5 x 105 cells/well.  Plate was incubated at 37°C for 1-3 hours.  
Following incubation, wells were washed once with warm PBS.  Cells were then lysed 
with 100 µL of 1X CT Green lysis buffer.  Fluorescence intensity was measured with a 
BioTek® Synergy 2 plate reader using a 485 nm excitation laser. 
 In the case of the vitronectin-coated plate, 5 x 104 CT Green-stained WBM cells 
were inoculated into each well.  DPT was added to the cells up to the final concentrations 
specified.  Wells were mixed via pipette before incubation and plate was incubated at 
37°C for 2 hours.  After incubation, wells were washed twice with PBS.  Cells were then 
lysed with 100 µL of 1X CT Green lysis buffer. 
  
WBM Adhesion to Endothelial Cells 
 HSCs undergoing homing have to first adhere to endothelial cells in the bone 
marrow before entering the hematopoietic niche.  Cells failing to adhere to the 
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vasculature will not be able to properly home to the niche.  We next wanted to determine 
if DPT affected the adhesion of WBM cells to endothelial cells.  To assay this, we 
cultured monolayers of endothelial cells and allowed WBM cells to adhere in the 
presence or absence of DPT. 
Monolayers of HDMECs were cultured in the wells of black, 96-well plates until 
confluent.  On the day prior to the experiment they were activated with TNF-α.  CT 
Green-stained WBM cells were suspended in RPMI and incubated with ~20 µg/mL DPT 
for 3 minutes prior to plating.  Cells were inoculated on top of the HDMECs at a density 
of 1 x 105 WBM cells/well.  Cells were allowed to adhere for 1 hour at 37°C.  Following 
incubation, wells were carefully washed once with warm PBS and cells were then lysed 
with 100 µL of 1X CT Green lysis buffer.  Fluorescence intensity was measured with a 
BioTek® Synergy 2 plate reader using a 485 nm excitation laser. 
 
Release Assay 
 After HSCs adhere to the endothelial cells in the bone marrow they need to 
maintain stable adhesion in order to undergo transendothelial migration.  We wondered if 
DPT was able to release WBM cells that were already adhered to endothelial cell 
monolayers.  To test this, we allowed WBM cells to adhere to endothelial monolayers, 
after which the cultures were incubated with DPT.  WBM cells that released from the 
endothelial monolayers were then measured. 
Monolayers of HDMECs were cultured in the wells of a 96-well plate until 
confluent.  CT Green-stained WBM cells were suspended in StemSpan™ media (#09650; 
StemCell Technologies).  WBM cells were inoculated on to the HDMECs at a density of 
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2 x 105 WBM cells per well.  WBM cells were then allowed to adhere to the endothelial 
monolayer overnight at 37°C.  The following day, wells were washed once with PBS to 
remove non-adhered cells.  Wells were then incubated with DPT at a concentration of 25 
µg/mL for 1 hour at 37°C.  Wells that did not receive DPT were inoculated with PBS 
instead.  After incubation, 90 µL of the supernatant was transferred to 10 µL of 10X CT 
Green lysis buffer.  Fluorescence intensity was measured with a BioTek® Synergy 2 
plate reader using a 485 nm excitation laser. 
 
Transwell Migration Assay 
 To determine if DPT had an effect on in vitro migration of WBM cells, we 
conducted transwell assays which included an endothelial monolayer that WBM cells had 
to migrate through. 
In this experiment, baskets of a 24-well, 5 µm pore transwell plate (#07200154; 
Fisher Scientific, Waltham, MA) were coated with 20 µg/mL fibronectin overnight at 
4°C.  The following day, 5 x 104 HUVECs were inoculated into each transwell basket 
and were cultured at 37°C until confluent.  The transwells were then transferred to wells 
containing 600 µL of RPMI ± 100 ng/mL sdf-1α.  CT Green-stained WBM cells were 
suspended in RPMI and were inoculated into each transwell at a density of 5 x 105 cells/ 
well.  Transwells that received DPT were inoculated with 1 µg of DPT, which was 
thoroughly mixed with the cells.  WBM cells were allowed to migrate overnight at 37°C.  
The following day, 550 µL of the bottom chamber was removed for analysis.  11,000 
PKH26 reference microbeads (#P7458; Sigma-Aldrich) and 0.5 µL Sytox Blue were 
added to each cell solution.  The number of WBM cells that migrated through the 
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transwell was counted using a BD FACSCanto™ RUO Special Order System flow 
cytometer with the reference beads as a counting gate. 
 
Blocking adhesion With Integrin Antibodies 
 Because DPT contains amino acid residue sequences predicted to be integrin 
binding motifs, we hypothesized that DPT may be interacting with or inhibiting integrin 
receptors important for the HSC homing process.  To confirm that specific integrins are 
important for cell adhesion, we used functional blocking antibodies against anti-integrin 
α3, α5, and β1. 
BMECs were activated with TNF-α, as described previously.  Cells were 
harvested using trypsin, stained with CT Green, and suspended in RPMI.  Cells were then 
incubated with integrin α3 + integrin β1 or integrin α5 + integrin β1 functional blocking 
antibodies.  Integrin α3 and integrin β1 antibodies were used at a dilution of 1:20 while 
the integrin α5 antibodies were used at a dilution of 1:100.  Cells were then inoculated on 
a black, 96-well plate at a density of 5 x 104 cells per well.  Cells were allowed to adhere 
at 37°C for 1 hour.  After incubation wells were washed once with warm PBS and were 
then lysed with 100 µL of 1X CT Green lysis buffer.  Fluorescence intensity was 
measured with a BioTek® Synergy 2 plate reader using a 485 nm excitation laser. 
 
Flow Cytometry 
 In order to confirm that DPT is binding to specific integrin receptors we used 
functional blocking antibodies and measured the number of cells bound with 
fluorescently labeled DPT.  First, we incubated endothelial cells with a combination of 
functional blocking antibodies to inhibit the integrin receptors VLA-3 and -5.  
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Fluorescently-labeled DPT was then incubated with the cells and flow cytometry was 
utilized to measure the number of cells that bound the labeled DPT after integrin 
blocking.  
For this experiment, confluent monolayers of HUVECs were harvested using non-
enzymatic dissociation buffer (#C5789; Sigma-Aldrich), according to manufacturer’s 
recommendations.  Cells were suspended in MACS buffer (PBS containing 5mg/mL 
BSA and 2 mM EDTA) and were aliquot into analysis tubes.  The cells were then 
incubated with α3 (1:20), α5 (1:100), or β1 (1:20), integrin blocking antibodies for 30 
minutes on ice.  After incubation with the antibodies, 1 µL of Alexa Fluor® 488-labled 
DPT (DPT-488) was added to each of the samples and incubated on ice for 5 minutes.  
After incubation, the cells were washed once with MACS buffer and re-suspended in 200 
µL of MACS buffer for analysis.  0.5 µg of propidium iodide (#P4864; Sigma-Aldrich) 
was added as a viability dye.  Cells were analyzed using a BD FACSCanto™ RUO 
Special Order System flow cytometer.   
 In the case of the VLA-3 and -5 blocking experiment, cells were incubated with a 
combination of integrin α3+β1 antibodies or integrin α5+β1 antibodies on ice for 30 
minutes.  Integrin α3 and β1 antibodies had been desalted and were used at a dilution of 
1:4 while the integrin α5 antibody was used at a dilution of 1:20.  Following incubation 
with antibodies, 1 µL DPT-488 and 1uL 1:10 fixable near-IR dead cell stain (#L10119; 
Life Technologies) were added to each sample and incubated on ice for 5 minutes.  Cells 
were washed once with MACS buffer and were re-suspended in 300 µL of 2% 
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paraformaldehyde/PBS solution and were incubated on ice for 15 minutes.  Cells were 
spun down and re-suspended in 200 µL PBS for analysis. 
Statistical Analysis 
 Data was presented as mean ± s.e.m. and analyzed using unpaired t test.  P values 
less than or equal to 0.05 were considered significant. 
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Results 
Dermatopontin Alters WBM and WKM Adhesion in vitro 
 Numerous ECM molecules and related integrin receptors have been implicated in 
HSC homing and maintenance of the hematopoietic niche97.  We hypothesized that DPT 
interacts with these ECM proteins and receptors, which blocks HSC homing.  Following 
an extensive literature search, we screened promising protein candidates in cellular 
adhesion assays to confirm if any play a role in the adhesion of WBM cells (Figure 2).  
ECM molecules screened were decorin, fibronectin, osteonectin, osteopontin, retronectin, 
and vitronectin.  We found that the recombinant protein retronectin, which is an active 
fragment of fibronectin, significantly increased adhesion of murine WBM cells, as 
expected98.  Likewise, the complete fibronectin molecule increased WBM cell adhesion, 
albeit not as robustly as retronectin.  Decorin quite significantly reduced overall adhesion, 
which seems to agree with some previous studies99,100.  Osteopontin and osteonectin had 
little effect on WBM cell adhesion.  Interestingly, vitronectin did not show a significant 
increase in adhesion in this experiment, despite being a well-known cell adhesion 
molecule (Figure 2A).  It should be noted that subsequent experimentation found 
vitronectin indeed promoted WBM cell adhesion (Figure 2B).  Based on this data 
decorin, fibronectin, and vitronectin were the focus of future experiments. 
 The ECM is a complex milieu of proteins and secreted factors, which together 
form a vast network involved in processes such as structural support, adhesion, and 
signaling.  The exact role of DPT in the ECM is not known, so we wanted to observe how 
WBM cells adhered to a “matrix” of proteins in the presence or absence of DPT.  To do 
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so, we coated a 96-well plate with a cocktail of decorin, fibronectin, osteonectin, 
osteopontin, and vitronectin.  We found that if DPT was added to the ECM cocktail 
during protein coating there would be fewer WBM cells that adhered (Figure 2C).  This 
contradicts previous studies74,78, which have shown that DPT can increase adhesion.  This 
suggests that DPT plays a somewhat ambiguous role in the modulation of cellular 
adhesion and that it may be cell-type specific or dependent on interactions with other 
molecules present in the ECM. 
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Figure 2: DPT reduces WBM cell adhesion to ECM coated wells 
 
Figure 2:  Adhesion of murine WBM cells in wells coated with individual ECM components (A-
B) or an ECM cocktail (C).  (A) Relative adherence of WBM cells plated in wells coated with 
Dec, FN, ON, OP, RN, or VN.  RN and FN significantly increased WBM cell adhesion while Dec 
significantly decreased adhesion.  (B) Relative adherence of WBM cells plated in wells coated 
with VN.  (C) Relative adherence of WBM cells plated in wells coated with an ECM cocktail 
(Dec, FN, ON, OP, and VN) ± 4 µg DPT.  DPT decreased WBM cell adhesion to this ECM 
cocktail.  ** P < 0.01, * 0.01 < P < 0.05, n=3.  CTL: control, Dec: decorin, DPT: dermatopontin, 
FN: fibronectin, ON: osteonectin, OP: osteopontin, RN: retronectin, VN: vitronectin. 
 
 
To further characterize DPT in the context of the hematopoietic cells, we 
performed additional adhesion assays.  Adhesion of WBM cells on to vitronectin-coated 
wells was significantly decreased in the presence of DPT (Figure 3A).  In a very 
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fundamental adhesion assay, we examined how DPT affects adhesion of WBM cells to 
uncoated plastic and found adhesion was drastically reduced when cells were incubated 
with DPT just prior to inoculation into a 96-well plate (Figure 3B), suggesting that DPT 
is binding to the WBM cells and somehow preventing their attachment to the plastic.  
And finally, we also observed that DPT could decrease the adhesion of zebrafish WKM 
cells to FN (Figure 3C), indicating that DPT may have a similar biological function in 
zebrafish.  Taken together, these data show that DPT can reduce the adhesiveness of 
marrow cells, possibly demonstrating an interesting physiological function of DPT.  
These observations suggest that DPT could act as a negative regulator of WBM cell 
adhesion in vivo, controlling their attachment to other cells or the ECM in the 
hematopoietic niche. 
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Figure 3: Dermatopontin reduces overall WBM and WKM cell adhesion in vitro 
 
Figure 3:  Adhesion of WBM or WKM cells in the presence or absence of DPT.  (A) Relative 
adherence of WBM cells plated in VN-coated wells ± 4 µg DPT.  DPT reduced cell adhesion to 
vitronectin.  (B) Adherence of WBM cells to plastic following incubation with 36 µg/mL DPT.  
This indicates that DPT is binding to WBM cells and preventing their attachment to the plastic.  
(C) Relative adherence of WKM cells plated in FN-coated wells ± 2 µg DPT.  DPT significantly 
reduced WKM cell adhesion to fibronectin.  CTL: control, DPT: dermatopontin, n=6. 
 
 
Dermatopontin Binds to Endothelial Cells and Alters Cell Adhesion in vitro 
 We hypothesized that adipocyte-secreted DPT may be interacting with endothelial 
cells in the bone marrow as well.  This interaction may be re-enforcing a physical barrier 
after radiation and chemotherapy, blocking migrating HSCs.  Our lab has previously 
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demonstrated that HUVECs rapidly take up Alexa Fluor® 488-labled DPT (DPT-488) in 
culture (unpublished data).  To demonstrate that DPT interacts with vasculature, we 
dissected intact aortas from mice and incubated them with rDPT (Figure 4). We used 
aortas since isolation of capillaries from bone marrow is extremely difficult.  
Immunohistochemistry (IHC) revealed DPT bound to endothelial cells in the lumen of 
the aorta (Figure 4A), while control aortas incubated with PBS did not reveal any DPT 
(endogenous DPT is likely too miniscule for detection) (Figure 4B).  This confirms our 
previous findings that DPT-488 binds to endothelial cells in vitro. 
 
Figure 4: Dermatopontin binds to vasculature ex vivo 
 
Figure 4:  IHC revealing DPT readily binds to endothelial in intact aorta.  Aorta were dissected 
and incubated with (A) and without (B) DPT.  IHC was performed against the 6X His-tagged 
DPT molecule.  Arrows indicate brown DPT staining in the lumen of the aorta.  25 µm scale bars. 
 
 Having demonstrated DPT can alter WBM and WKM cell adhesion, we predicted 
it would do the same for endothelial cells.  To confirm, we performed adhesion assays 
using a variety of endothelial cell lines.  We found that DPT had no influence on human 
umbilical vein endothelial cell (HUVEC) cell adhesion to plastic (Figure 5A).  However, 
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HUVEC adhesion to vitronectin is significantly decreased with the addition of DPT 
(Figure 5B), supporting the hypothesis that DPT dynamically exerts its influence on cell 
adhesion and may depend on the presence of other ECM molecules.  These findings also 
corroborate the data showing WBM cell adhesion to vitronectin was also decreased in the 
presence of DPT. 
 
Figure 5:  Dermatopontin decreases HUVEC adhesion to vitronectin 
 
Figure 5: HUVEC adhesion to plastic (A) or vitronectin (B) in the presence or absence of DPT.  
(A) Relative adherence of HUVECs to plastic wells incubated with 20 µg/mL DPT.  HUVECs 
bound to DPT-coated wells and control wells equally.  (B) Relative adherence of HUVECs to a 
vitronectin-coated plate ± 1 µg DPT.  DPT reduced HUVEC adhesion to vitronectin.  CTL: 
control, DPT: dermatopontin, n=6. 
 
 
 In addition to HUVECs, we have also assayed human dermal microvascular 
endothelial cells (HDMECs) and VeraVec™ mouse bone marrow endothelial cells 
(BMECs)101,102.  In agreement with data thus far, DPT decreased adhesion of HDMECs 
to plastic (Figure 6A) and fibronectin (Figure 6B).  Activation of HDMECs with TNF-α 
does not substantially change the degree to which DPT decreases adhesion (Figure 6C), 
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indicating DPT is not affecting molecules upregulated by TNF-α in HDMECs.  Like the 
other endothelial cells, adhesion of BMECs to plastic was also significantly diminished 
upon incubation with DPT (Figure 7).  Interestingly, DPT had a more substantial effect 
on the bone marrow endothelial cells compared to the other endothelial cell lines.  This 
indicates that DPT may have a more robust interaction with support cells in the bone 
marrow.   
Altogether, our adhesion assays have consistently shown that DPT negatively 
influences cell adhesion under numerous conditions, including a variety of endothelial 
cells, as well as WBM and WKM cell types. 
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Figure 6: Dermatopontin decreases overall adhesion of HDMECs 
 
Figure 6: HDMEC adhesion to plastic (A) or fibronectin (B) in the presence or absence of DPT 
and TNF-α activation (C).  (A) Relative adherence of HDMECs to plastic after incubation with 
36 µg/mL DPT.  DPT decreased cell adhesion as seen previously.  (B) Relative adherence of 
HDMECs to fibronectin-coated wells ± 1 µg DPT.  DPT significantly reduced HDMEC adhesion 
to fibronectin.  (C) Effect of TNF-α activation of HDMECs adhering to plastic.  TNF-α activation 
of HDMECs did not change the degree to which DPT alters adhesion.  CTL: control, DPT: 
dermatopontin, HDMEC: human dermal microvascular endothelial cell, TNF-a: tumor necrosis 
factor-alpha, n=6. 
 
 
 
 
 
  38 
Figure 7: Dermatopontin decreases BMEC adhesion 
 
Figure 7: Relative adherence for BMEC adhesion to plastic after incubation with 36 µg/mL DPT.  
DPT drastically reduced adhesion of BMECs to plastic indicating substantial interaction with 
DPT compared to other cell types.  BMEC: bone marrow endothelial cell, CTL: control, DPT: 
dermatopontin, n=6. 
 
Loss of Adhesion is Dose-Dependent 
 We next determined if the loss of cell adhesion was dependent on the amount of 
DPT added to the system (Figure 8).  For these experiments we coated wells with 
increasing concentrations of DPT.  In agreement with previous data, we found that DPT 
reduced adhesion of HDMECs in vitro.  This effect happened in a dose-dependent 
manner, with a significant reduction in adhesion starting at a DPT concentration of 10 
µg/mL (Figure 8A).   
Mesenchymal cells are another important cell type present in the hematopoietic 
niche.  Because of this, we were curious if DPT affected adhesion of human 
mesenchymal stem cells (huMSCs) as well.  DPT had a significant effect on huMSC 
adhesion, in a dose-dependent manner (Figure 8B), suggesting the importance of DPT in 
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regulating the adhesiveness of cell types found in the bone marrow.  Further testing 
revealed that WBM cell adhesion to plastic (Figure 8C) and to vitronectin (Figure 8D) 
were both affected by DPT in a dose-dependent manner as well.  To determine the dose-
response with a more defined population of hematopoietic cells, we performed an 
adhesion assay using Sca1+ selected hematopoietic cells.  Consistent with previous data, 
we found that DPT affects Sca1+ cell adhesion in a dose-dependent manner (Figure 8E).  
Because Sca1+ cells represent hematopoietic cells in WBM, this indicates that DPT also 
directly influences adhesion of hematopoietic cells in addition to endothelial cells and 
other support cells found in the hematopoietic niche. 
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Figure 8: Loss of cell adhesion is dose-dependent 
 
Figure 8:  Relative adherence of HDMECs (A), huMSCs (B), WBM cells (C, D), and Sca1+ cells 
(E) to increasing concentrations of DPT.  DPT decreased cell adhesion for each cell type in a 
dose-dependent manner.  *** P < 0.001, ** 0.001 < P < 0.01, * 0.01 < P < 0.05, n=6.  DPT: 
dermatopontin, HDMEC: human dermal microvascular endothelial cell, huMSCs: human 
mesenchymal stem cells. 
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Dermatopontin Reduces WBM Attachment to Endothelial Cells in Vitro 
 Endothelial cells constitute the first major physical barrier to homing HSCs.  In 
order to undergo extravasation, HSCs need to first undergo rolling adhesion to bind to 
endothelial cells.  This is mediated by P- and E-selectins.  Following this, tighter 
adherence mediated by integrin receptors occurs.  We wanted to know if DPT affected 
WBM (which contains HSCs) adherence to endothelial cells, so we cultured a monolayer 
of HDMECs and adhered WBM cells on top of them (Figure 9).  We found that 
activating the HDMECs with TNF-α lead to an overall increase in the number of adherent 
WBM cells.  This was expected as TNF-α activation of endothelial cells causes the 
upregulation of selectin molecules and various integrin ligands, which are integral in the 
initial adherence of HSCs to endothelial cells in vivo103–105.  As hypothesized, 
significantly fewer WBM cells adhered to activated HDMECs in the presence of DPT.  
However, it is unknown if this observation is due to a reduction in HSC or stromal cell 
adhesion to endothelial cells, which will have to be explored further with more defined 
populations of WBM cells.  Because there was not a statistical difference between DPT 
and control treatments for un-activated HDMECs, the degree to which DPT exerts its 
influence on adhesion is likely dependent on the relative abundance of other adhesion 
molecules that are upregulated by TNF-α activation.  This implies that the pre-transplant 
conditioning regimen may be important and required for attachment to occur. 
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Figure 9: Dermatopontin reduces WBM cell adhesion to endothelial cells 
 
Figure 9: Relative adherence of WBM cells plated on top of HDMEC monolayers in the 
presence or absence of DPT.  The fluorescently-labeled WBM cells were lysed after incubation.  
TNF-α activation of HDMECs nearly doubled the number of WBM cells that adhered to 
endothelial cells.  DPT significantly reduced WBM cell adhesion to TNF-α-activated endothelial 
cells.  CTL: control, DPT: dermatopontin, HDMEC: human dermal microvascular endothelial 
cell, TNF-α: tumor necrosis factor-alpha, n=12, n.s. = not significant.   
 
Dermatopontin Releases Adhered WBM Cells 
 After observing DPT can reduce WBM cell adhesion to endothelial monolayers, 
we wondered if adding DPT to already adhered WBM cells would cause them to release.  
We developed a novel release assay which measures whether or not fluorescently labeled 
WBM cells un-attach from the endothelial cells when DPT was added to the system, as 
was measured using a plate reader and the supernatant from each well.  Indeed, we 
observed that incubating adhered WBM cells with DPT could cause a substantial number 
of cells to release from endothelial monolayers (Figure 10).  It should be noted, however, 
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that this experiment has only been performed once so further analysis is needed to 
confirm this phenomenon.   
 
Figure 10: Dermatopontin causes adhered WBM cells to release from endothelial 
cells 
 
Figure 10:  Release assay measuring whether or not DPT can cause already adhered WBM cells 
to release from endothelial cells into the media.  After adhering to endothelial monolayers, 
fluorescently labeled WBM cells were incubated in the presence or absence of DPT.  After 
incubation, the media was removed from the wells and any cells contained within were lysed.  
CTL: control, DPT: dermatopontin, RFUs: relative fluorescence units, n=10.   
 
 
Dermatopontin Influences WBM Migration in vitro 
 Armed with the knowledge that DPT can reduce WBM cell adhesion to 
endothelial cells, we next examined if DPT affected WBM cell homing in transwell 
assays (Figure 11).  In this assay, transwell baskets were first coated with fibronectin and 
then a monolayer of HUVECs.  Cells did not migrate through the transwells unless SDF-
1 was present in the bottom chamber, as expected, and DPT did not affect migration on 
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its own.  The number of WBM cells that migrated through the transwell was significantly 
reduced when fibronectin was pre-coated on to the transwells.  DPT was able 
significantly increase the number of migrated cells in the presence of fibronectin.  Based 
on this evidence, we hypothesized that fibronectin was tightly binding to integrin 
receptors on migrating WBM cells and preventing further migration, trapping the cells at 
the transwell interface.  We further hypothesized that when DPT was added to the system 
it interfered with these integrin receptors and inhibited their engagement with fibronectin, 
allowing the migrating WBM cells to more easily pass through the fibronectin coated 
transwells.  We are currently investigating this phenomenon further. 
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Figure 11: Dermatopontin affects WBM cell migration in transwell migration assays 
 
Figure 11:  Transwell migration assaying showing the effect of DPT on WBM cell homing 
through a FN coated transwell covered in a monolayer of endothelial cells.  Transwell baskets 
were coated with FN prior to seeding with HUVECs.  Control wells were not coated with FN, but 
had a HUVEC monolayer.  After HUVECs formed a confluent monolayer in the basket, CT 
Green-stained WBM cells were migrated against a gradient of SDF-1.  Control migrations 
without sdf-1 are also represented.  1 µg of DPT was mixed with the cells prior to inoculation into 
the transwell basket.  The number of cells which migrated into the bottom chamber was counted 
the next day using a flow cytometer.  DPT: dermatopontin, FN: fibronectin, HUVECs: human 
umbilical vein endothelial cells, SDF-1: stromal derived factor-1, n=10.   
 
 
Identification of Dermatopontin-Binding Integrins 
 We hypothesized that DPT may be interacting with integrin receptors and 
possibly blocking their function.  Because the integrin VLA-5 is important in cell 
adhesion and homing, we chose to focus our efforts on characterizing its interaction with 
DPT.  We also focused on a relatively understudied integrin, VLA-3, because it was 
reported in the literature to interact with DPT74.  We first wanted to confirm that VLA-3 
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and VLA-5 play a role in cellular adherence, so we incubated BMECs with functional 
blocking antibodies against VLA-3 (anti-integrin α3 + anti-integrin β1 antibodies) and 
VLA-5 (anti-integrin α5 + anti-integrin β1 antibodies) and saw a marked decrease in cell 
adhesion to plastic (Figure 12), confirming the role of these integrins in cell adhesion to 
plastic. 
Figure 12: Integrin blocking antibodies reduce BMEC adhesion 
 
Figure 12:  Relative adherence of BMECs incubated with integrin blocking antibodies prior to 
plating.  The fluorescently-labeled WBM cells were lysed after incubation.  Blocking both 
integrins significantly decreased cell adhesion compared to the control.  * P < 0.01, n=6.  BMEC: 
bone marrow endothelial cell, CTL: control, VLA: very-late antigen.   
 
 To determine if DPT was directly interacting with the integrin receptors VLA-3 
and -5 on endothelial cells, we first incubated HUVECs with functional blocking 
antibodies against the α3, α5, and β1 subunits followed by incubation with DPT-488.  We 
expected the blocking antibodies would prevent the labeled DPT from efficiently binding 
to the HUVECs.  However, we saw no observable difference between the blocking 
antibodies and control treatments (Figure 13A).  It was thought that the antibodies for 
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each individual subunit were not enough to prevent DPT binding, so we instead blocked 
with an antibody combination consisting of α3 + β1 (VLA-3) or α5 + β1 (VLA-5).  The 
combination of α3 and β1 antibodies significantly decreased the number of HUVECs 
binding DPT-488 (Figure 13B).  These findings suggest the integrin receptor VLA-3 is 
directly involved with dermatopontin binding to endothelial cells. This evidence also 
agrees with a previous report indicating VLA-3 interacts with DPT during keratinocyte 
adhesion.  It should be noted that these data were obtained from a single experiment that 
has not been repeated yet. 
 
Figure 13: Antibodies against VLA-3 prevent HUVECs from binding DPT 
 
 
Figure 13:  Relative percentage of cells bound to DPT-488 after incubation with individual (A) 
or a mixture (B) of integrin blocking antibodies.  (A) Functional blocking antibodies against 
integrins α3, α5, and β1 were incubated with HUVECs prior to addition of DPT-488.  These 
antibodies on their own did not significantly reduce DPT-488 binding to HUVECs.  (B) 
Functional blocking antibodies against α3 + β1 (VLA-3) or α5 + β1 (VLA-5) were incubated with 
HUVECs prior to addition of DPT-488.  We found that blocking VLA-3 reduced the number of 
cells binding to labeled DPT.  * P < 0.01, n=3.  DPT-488: Alexa Fluor® 488-labeled 
dermatopontin, HUVEC: human umbilical vein endothelial cell, VLA: very-late antigen. 
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Discussion 
 Unlike other non-collagenous proteins, dermatopontin has not been extensively 
studied despite being a widely distributed throughout the body.  After it was discovered, 
experiments showed that DPT interacts with a number of other ECM molecules including 
collagen and fibronectin.  However, the exact physiological function of DPT has not been 
described.  These former studies primarily investigated DPT in the context of the skin 
and there have been no reports on the role of DPT in the hematopoietic system or bone 
marrow.  Therefore, the goals of this study were to 1) characterize how DPT affects 
adhesion of hematopoietic and endothelial cells in vitro and 2) determine a possible 
mechanism by which DPT can negatively regulate HSC homing. 
 As previously described, our lab found that DPT negatively regulates HSC 
homing in mice.  Mice treated with DPT prior to HCT show poor homing and 
engraftment compared to their untreated counterparts, which has been demonstrated in 
numerous transplant experiments.  We found that DPT is secreted in the bone marrow by 
resident adipocytes, especially after treatment with radiation.  Previous studies have 
hypothesized that DPT may be involved in wound healing processes in the skin and that 
it interacts with other ECM proteins to modify cell adhesion71,78.  Similarly, we 
hypothesized that adipocytes highly express DPT in response to the massive injury 
caused by radiation and chemotherapy.  We believe this secreted DPT then hinders 
successful HSC homing and engraftment, likely by modification of cell adhesion via 
altering the ECM or integrin receptors. 
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 Contrary to previous reports that showed DPT increased cell adhesion74,78, we 
consistently found that DPT decreased the overall cell adhesion of WBM cells and 
various types of endothelial cells.  These results may indicate that DPT has a quite 
dynamic effect on cell adhesion.  This effect may depend on the cell type and the 
presence of addition ECM molecules.  In agreement with this, we found that in the case 
of HUVEC adhesion, DPT would not decrease cell adhesion unless in the presence of 
vitronectin. 
 Interestingly, we found that DPT reduces WBM cell adhesion to endothelial cells.  
We also showed that DPT could release WBM cells that were already adhered to 
endothelial cells.  These results hint at a possible mechanism by which DPT can 
negatively regulate homing.  DPT secreted by adipocytes and other cells into the bone 
marrow may be “coating” the vasculature and preventing transplanted HSCs from 
efficiently adhering to the endothelial cells.  Confirming this, we demonstrated that DPT 
readily coats the lumen of intact aorta.  As an alternative mechanism, DPT secreted into 
the blood may also be binding the circulating HSCs and preventing them from 
undergoing necessary tight adhesion to endothelial cells.  In the case of either mechanism 
the HSCs would not be able to reach the hematopoietic niche since they would be trapped 
in circulation.  This has been preliminarily confirmed by CFU assays, which showed an 
increased number of CFUs in the peripheral blood of DPT-treated animals compared to 
controls.  Altogether, these data may indicate that DPT has a physiological function that 
negatively regulates the homing process during endogenous HSC mobilization. 
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 However, the exact mechanism by which DPT impedes homing remains unclear.  
A number of previous papers have demonstrated the importance of integrin receptors 
binding DPT73,74,79.  We believe that DPT lining the lumen of the bone marrow 
vasculature or coating circulating WBM cells may be inhibiting critical integrin 
receptors, likely VLA-3 and -5, thus preventing stable adhesion of the HSC to the 
endothelial cells.  In this study we were able to allude to the involvement of VLA-3 in 
binding to labeled DPT.  To further test this hypothesis we are now conducting pull-down 
assays to look if VLA-3 and -5 directly bind and interact with DPT.  VLA-3 knockout 
mice and cell lines will also be a useful tool in validating our findings. 
We are also in active development of a DPT knockout mouse to further aid in our 
investigation of DPT (unfortunately, colonies of the previously developed knockout 
mouse were completely destroyed).  If our hypotheses are correct, DPT knockout mice 
should engraft substantially better due to a lack of DPT in their system.  This will be the 
first documentation of a secreted adipokine able to impede hematopoietic cell homing. 
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